(19)
(11) EP 4 739 654 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24740406.4

(22) Date of filing: 05.07.2024
(51) International Patent Classification (IPC): 
C07D 205/04(2006.01)
A61K 31/397(2006.01)
A61P 25/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 25/00; C07D 205/04
(86) International application number:
PCT/EP2024/068995
(87) International publication number:
WO 2025/008504 (09.01.2025 Gazette 2025/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 06.07.2023 EP 23183804

(71) Applicant: Integrative Research Laboratories Sweden AB
413 46 Göteborg (SE)

(72) Inventors:
  • KAZA ONOKA, Galina
    2108 M rupes novads (LV)
  • EKAWA, Bruno
    6828AS Arnhem (NL)
  • FERNANDEZ, Ana
    1183BR Amstelveen (NL)
  • BUKSA, Maija
    1004 Riga (LV)
  • NGUYEN, Lien
    431 49 Mölndal (SE)
  • WATERS, Nicholas
    413 19 Göteborg (SE)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) PHARMACEUTICALLY ACCEPTABLE SALTS OF 3-(2,3-DIFLUOROPHENOXY)AZETIDINE AND USES THEREOF